Clinical trial · Observational
CD155 Expression in Acute Myeloid Leukemia
Prognostic and Predictive Values of CD155 in Patients With Acute Myeloid Leukemia
NCT06369662CI-TRIAL-00081665completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020. CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Leukemia, Myeloid | Myeloid Leukemia | ALIAS | 0.90 |
| Leukemia, Myeloid, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bone marrow aspiration | Diagnostic Test | — | UNRESOLVED |
| Complete blood count | Diagnostic Test | — | UNRESOLVED |
| Cytogenetic testing | Diagnostic Test | — | UNRESOLVED |
| Flow cytometric immunophenotyping | Diagnostic Test | — | UNRESOLVED |
| FLT3-ITD using High resolution melting curve (HRM) analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AML Patients
- description
- Adult patients (from 18 - 60 years) diagnosed as AML
- interventionNames
- Diagnostic Test: Flow cytometric immunophenotyping
- Diagnostic Test: Complete blood count
- Diagnostic Test: Bone marrow aspiration
- Diagnostic Test: Cytogenetic testing
- Diagnostic Test: FLT3-ITD using High resolution melting curve (HRM) analysis
Primary outcomes (1)
- measure
- CD155 expression in AML
- timeFrame
- 2 years
- description
- Study the CD155 expression by flow cytometry
Secondary outcomes (2)
- measure
- CD155 expression with patients' clinical data
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with newly diagnosed AML. * Age group: patients more than 18 years old and less than 60 years. * Patients receiving induction chemotherapy 3\&7 at South Egypt Cancer Institute. Exclusion Criteria: * Patients less than 18 years old and over 60 years. * Patients with concurrent malignancy. * Secondary AML. * Acute Promyelocytic leukemia (AML-M3).
References
Publications (8)
- BACKGROUNDDougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. PMID 28258695
- BACKGROUNDGao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017 Oct;108(10):1934-1938. doi: 10.1111/cas.13324. Epub 2017 Aug 18. PMID 28730595
- BACKGROUNDGorvel L, Olive D. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies. F1000Res. 2020 May 13;9:F1000 Faculty Rev-354. doi: 10.12688/f1000research.22877.1. eCollection 2020. PMID 32489646
- BACKGROUNDLi XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14. PMID 29757192
- BACKGROUNDLiu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clin Immunol. 2018 May;190:32-40. doi: 10.1016/j.clim.2018.02.009. Epub 2018 Mar 15. PMID 29477343
- BACKGROUNDSiegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. PMID 31912902
- BACKGROUNDZhang H, Yang Z, Du G, Cao L, Tan B. CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers. Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033820980088. doi: 10.1177/1533033820980088.